Friday 6 November 2026 Export BIO.B’s income statement to Excel — free account

Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.

Revenue: +0.52%
EPS: +234.9%
Free cash flow: +8.07%
Total debt: +0.11%

Quarter to September 2026, against a year earlier

Operating cash flow growth 3 yrs

379.50 15.35 +4.22%

Follow BIO.B

Alert me

Market cap: $10.3B
P/E: 9.9×
Fwd P/E: —
Dividend yield: —
F-score: 5/9
Altman Z: 3.24
Beneish M: −2.29
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Bio-Rad Laboratories, Inc. (BIO.B) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2017: revenue by segment, and margins
Clinical Diagnostics	1,361	63.00%
Life Science	785	36.35%
All Other Segments	14	0.66%
Gross margin		54.98%
Operating margin		5.52%
Pre-tax margin		4.53%

Revenue by segment $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009
Clinical Diagnostics	1,562 60.47%	1,538 59.92%	1,489 55.75%	1,451 51.78%	1,516 51.87%	1,305 51.27%	1,412 61.08%	1,412 61.67%	1,361 62.99%	1,323 63.98%	1,310 64.89%	1,432 65.85%	1,408 66.02%	1,366 65.99%	1,364 65.77%	1,265 65.66%	1,140 63.89%
Life Science	1,021 39.53%	1,028 40.06%	1,178 44.12%	1,347 48.08%	1,401 47.93%	1,232 48.39%	886 38.32%	862 37.64%	785 36.35%	731 35.33%	695 34.42%	728 33.48%	710 33.29%	688 33.27%	695 33.50%	648 33.63%	632 35.39%
All Other Segments	0 0.00%	1 0.02%	4 0.13%	4 0.14%	6 0.20%	9 0.34%	14 0.60%	16 0.69%	14 0.66%	14 0.69%	14 0.69%	14 0.66%	15 0.69%	15 0.74%	15 0.72%	14 0.71%	13 0.72%
Revenue	2,583	2,567	2,671	2,802	2,923	2,546	2,312	2,289	2,160	2,068	2,019	2,175	2,133	2,069	2,074	1,927	1,784

Operating income by segment $m, and margin

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009
Clinical Diagnostics	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Life Science	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
All Other Segments	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Reportable Segment [Member] (Deprecated 2013-01-31)	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Corporate and other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Operating income	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

Revenue by region $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009
UNITED STATES	1,023 39.59%	1,042 40.58%	1,122 42.00%	1,156 41.24%	1,131 38.69%	1,005 39.47%	899 38.89%	864 37.72%	800 37.04%	771 37.26%	735 36.40%	705 32.41%	678 31.78%	657 31.74%	631 30.43%	601 31.16%	566 31.71%
Europe	882 34.14%	834 32.50%	820 30.69%	852 30.40%	947 32.40%	858 33.69%	770 33.32%	792 34.59%	759 35.11%	742 35.89%	764 37.82%	902 41.46%	886 41.55%	837 40.45%	896 43.23%	843 43.72%	814 45.64%
Asia Pacific	513 19.87%	522 20.32%	563 21.08%	639 22.82%	688 23.56%	547 21.47%	505 21.85%	496 21.64%	461 21.35%	427 20.65%	392 19.42%	418 19.20%	413 19.38%	426 20.57%	398 19.21%	348 18.05%	292 16.34%
Americas	165 6.40%	169 6.60%	167 6.23%	155 5.55%	157 5.36%	137 5.37%	137 5.94%	138 6.04%	140 6.48%	128 6.20%	129 6.36%	151 6.94%	156 7.30%	150 7.24%	148 7.12%	136 7.07%	113 6.31%
Revenue	2,583	2,567	2,671	2,802	2,923	2,546	2,312	2,289	2,160	2,068	2,019	2,175	2,133	2,069	2,074	1,927	1,784

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.